Does the media favor GHRS or SPRY?

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than GH Research. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for GH Research. GH Research's average media sentiment score of 1.01 beat ARS Pharmaceuticals' score of -0.05 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SPRY or ETON?

In the previous week, ARS Pharmaceuticals had 16 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 3 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.78 beat ARS Pharmaceuticals' score of -0.05 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SPRY or ANIP?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 15 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.83 beat ARS Pharmaceuticals' score of -0.05 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, INVA or SPRY?

Innoviva has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $440.00M 3.47 $271.17M $4.10 5.16 ARS Pharmaceuticals $116.93M 3.52 -$171.30M -$2.18 N/A

Does the media refer more to INVA or SPRY?

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.44 beat ARS Pharmaceuticals' score of -0.05 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVLN or SPRY?

In the previous week, ARS Pharmaceuticals had 11 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 8 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.26 beat ARS Pharmaceuticals' score of -0.05 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

ARS Pharmaceuticals (SPRY) Competitors

$4.11 -0.04 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$4.12 +0.00 (+0.12%)

As of 04:19 PM Eastern

Compare

SPRY vs. GHRS, ETON, ANIP, INVA, and AVLN

Should you buy ARS Pharmaceuticals stock or one of its competitors? ARS Pharmaceuticals's main competitors and comparable companies include GH Research (GHRS), Eton Pharmaceuticals (ETON), ANI Pharmaceuticals (ANIP), Innoviva (INVA), and Avalyn Pharma (AVLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ARS Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

56.9% of GH Research shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than GH Research. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for GH Research. GH Research's average media sentiment score of 1.01 beat ARS Pharmaceuticals' score of -0.05 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. GH Research's return on equity of -20.86% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

GH Research has higher earnings, but lower revenue than ARS Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
ARS Pharmaceuticals	$116.93M	3.52	-$171.30M	-$2.18	N/A

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

GH Research currently has a consensus price target of $45.00, suggesting a potential upside of 59.60%. ARS Pharmaceuticals has a consensus price target of $26.40, suggesting a potential upside of 538.45%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

GH Research beats ARS Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

ARS Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Eton Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$116.93M	3.52	-$171.30M	-$2.18	N/A
Eton Pharmaceuticals	$79.95M	20.03	-$4.60M	$0.38	147.49

Eton Pharmaceuticals has a net margin of 12.02% compared to ARS Pharmaceuticals' net margin of -184.24%. Eton Pharmaceuticals' return on equity of 40.13% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ARS Pharmaceuticals currently has a consensus target price of $26.40, indicating a potential upside of 538.45%. Eton Pharmaceuticals has a consensus target price of $67.50, indicating a potential upside of 20.44%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 16 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 3 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.78 beat ARS Pharmaceuticals' score of -0.05 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Eton Pharmaceuticals beats ARS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to ANI Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

ARS Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 15 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.83 beat ARS Pharmaceuticals' score of -0.05 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$116.93M	3.52	-$171.30M	-$2.18	N/A
ANI Pharmaceuticals	$978.38M	1.82	$78.34M	$4.64	16.68

ANI Pharmaceuticals has a net margin of 11.07% compared to ARS Pharmaceuticals' net margin of -184.24%. ANI Pharmaceuticals' return on equity of 27.37% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

ARS Pharmaceuticals currently has a consensus target price of $26.40, suggesting a potential upside of 538.45%. ANI Pharmaceuticals has a consensus target price of $103.00, suggesting a potential upside of 33.11%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ANI Pharmaceuticals beats ARS Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Innoviva has a net margin of 81.19% compared to ARS Pharmaceuticals' net margin of -184.24%. Innoviva's return on equity of 28.03% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$440.00M	3.47	$271.17M	$4.10	5.16
ARS Pharmaceuticals	$116.93M	3.52	-$171.30M	-$2.18	N/A

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.44 beat ARS Pharmaceuticals' score of -0.05 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva currently has a consensus target price of $34.75, indicating a potential upside of 64.38%. ARS Pharmaceuticals has a consensus target price of $26.40, indicating a potential upside of 538.45%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Innoviva has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Innoviva beats ARS Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, ARS Pharmaceuticals had 11 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 8 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.26 beat ARS Pharmaceuticals' score of -0.05 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avalyn Pharma has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
ARS Pharmaceuticals	$116.93M	3.52	-$171.30M	-$2.18	N/A

Avalyn Pharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Avalyn Pharma's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Avalyn Pharma presently has a consensus price target of $60.00, suggesting a potential upside of 87.68%. ARS Pharmaceuticals has a consensus price target of $26.40, suggesting a potential upside of 538.45%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Avalyn Pharma and ARS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$411.21M	$12.45B	$7.21B	$13.72B
Dividend Yield	N/A	2.64%	2.57%	12.64%
P/E Ratio	-1.90	797.27	274.65	25.48
Price / Sales	3.52	799.15	681.69	100.02
Price / Cash	N/A	87.33	77.01	51.20
Price / Book	3.56	10.54	10.50	6.33
Net Income	-$171.30M	$2.81B	$3.48B	$358.24M
7 Day Performance	-13.13%	2.65%	0.94%	1.25%
1 Month Performance	-34.37%	3.06%	0.03%	-2.03%
1 Year Performance	-58.36%	3.59%	18.24%	5.16%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	1.6791 of 5 stars	$4.11 -1.0%	$26.40 +542.3%	-56.6%	$408.73M	$116.93M	N/A	200
GHRS GH Research	2.5296 of 5 stars	$27.89 +2.5%	$45.00 +61.3%	+129.8%	$1.87B	N/A	N/A	73	News Coverage Positive News
ETON Eton Pharmaceuticals	4.5092 of 5 stars	$57.62 +0.9%	$67.50 +17.1%	+222.8%	$1.63B	$79.95M	151.63	44	Positive News
ANIP ANI Pharmaceuticals	4.0303 of 5 stars	$70.40 +0.3%	$105.57 +50.0%	-20.9%	$1.61B	$883.37M	15.17	970	Insider Trade
INVA Innoviva	2.5811 of 5 stars	$20.90 +1.2%	$34.75 +66.3%	+8.6%	$1.49B	$440.00M	5.10	159	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. GHRS, ETON, ANIP, INVA, and AVLN

How does ARS Pharmaceuticals compare to GH Research?

Summary

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to Innoviva?

Summary

How does ARS Pharmaceuticals compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. GHRS, ETON, ANIP, INVA, and AVLN

How does ARS Pharmaceuticals compare to GH Research?

Do insiders & institutionals hold more shares of GHRS or SPRY?

Does the media favor GHRS or SPRY?

Is GHRS or SPRY more profitable?

Which has better valuation and earnings, GHRS or SPRY?

Which has more volatility & risk, GHRS or SPRY?

Do analysts recommend GHRS or SPRY?

Summary

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

Which has more volatility and risk, SPRY or ETON?

Which has stronger valuation and earnings, SPRY or ETON?

Is SPRY or ETON more profitable?

Do insiders and institutionals have more ownership in SPRY or ETON?

Do analysts prefer SPRY or ETON?

Does the media refer more to SPRY or ETON?

Summary

How does ARS Pharmaceuticals compare to ANI Pharmaceuticals?

Which has more volatility and risk, SPRY or ANIP?

Does the media favor SPRY or ANIP?

Do institutionals & insiders have more ownership in SPRY or ANIP?

Which has preferable earnings and valuation, SPRY or ANIP?

Is SPRY or ANIP more profitable?

Do analysts prefer SPRY or ANIP?

Summary

How does ARS Pharmaceuticals compare to Innoviva?

Is INVA or SPRY more profitable?

Do insiders & institutionals believe in INVA or SPRY?

Which has stronger valuation and earnings, INVA or SPRY?

Does the media refer more to INVA or SPRY?

Do analysts prefer INVA or SPRY?

Which has more risk and volatility, INVA or SPRY?

Summary

How does ARS Pharmaceuticals compare to Avalyn Pharma?

Does the media prefer AVLN or SPRY?

Do insiders and institutionals hold more shares of AVLN or SPRY?

Which has preferable valuation & earnings, AVLN or SPRY?

Is AVLN or SPRY more profitable?

Do analysts rate AVLN or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools